1. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer. (November 2017) Authors: Soria, Jean-Charles; Adjei, Alex A.; Bahleda, Rastilav; Besse, Benjamin; Ferte, Charles; Planchard, David; Zhou, Jing; Ware, Joseph; Morrissey, Kari; Shankar, Geetha; Lin, Wei; Schutzman, Jennifer L.; Dy, Grace K.; Groen, Harry J.M. Journal: European journal of cancer Issue: Volume 86(2017) Page Start: 186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Issue 10 (October 2017) Authors: Planchard, David; Smit, Egbert F; Groen, Harry J M; Mazieres, Julien; Besse, Benjamin; Helland, Åslaug; Giannone, Vanessa; D'Amelio, Anthony M; Zhang, Pingkuan; Mookerjee, Bijoyesh; Johnson, Bruce E Journal: Lancet oncology Issue: Volume 18:Issue 10(2017:Oct.) Page Start: 1307 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice. Issue 2 (10th August 2017) Authors: Tomasini, Pascale; Brosseau, Solenn; Mazières, Julien; Merlio, Jean-Philippe; Beau-Faller, Michèle; Mosser, Jean; Wislez, Marie; Ouafik, L'Houcine; Besse, Benjamin; Rouquette, Isabelle; Debieuvre, Didier; Escande, Fabienne; Westeel, Virginie; Audigier-Valette, Clarisse; Missy, Pascale; Langlais, ... Journal: European respiratory journal Issue: Volume 50:Issue 2(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. Issue 2 (March 2017) Authors: Remon, Jordi; Besse, Benjamin Journal: Current opinion in oncology Issue: Volume 29:Issue 2(2017:Mar.) Page Start: 97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. Issue 2 (March 2017) Authors: Remon, Jordi; Besse, Benjamin Journal: Current opinion in oncology Issue: Volume 29:Issue 2(2017:Mar.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. (November 2017) Authors: Ferrara, Roberto; Mezquita, Laura; Auclin, Edouard; Chaput, Nathalie; Besse, Benjamin Journal: Cancer treatment reviews Issue: Volume 60(2017) Page Start: 60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non–small cell lung cancer. (November 2017) Authors: Mahjoubi, Linda; Gazzah, Anas; Marabelle, Aurélien; Le Roy Ladurie, François; Lambotte, Olivier; Caramella, Caroline; Adam, Julien; Besse, Benjamin; Soria, Jean-Charles Journal: European journal of cancer Issue: Volume 85(2017) Page Start: 155 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. (October 2017) Authors: Facchinetti, Francesco; Bluthgen, Maria Virginia; Tergemina-Clain, Gabrielle; Faivre, Laura; Pignon, Jean-Pierre; Planchard, David; Remon, Jordi; Soria, Jean-Charles; Lacroix, Ludovic; Besse, Benjamin Journal: Lung cancer Issue: Volume 112(2017) Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Issue 12 (December 2017) Authors: Shaw, Alice T; Felip, Enriqueta; Bauer, Todd M; Besse, Benjamin; Navarro, Alejandro; Postel-Vinay, Sophie; Gainor, Justin F; Johnson, Melissa; Dietrich, Jorg; James, Leonard P; Clancy, Jill S; Chen, Joseph; Martini, Jean-François; Abbattista, Antonello; Solomon, Benjamin J Journal: Lancet oncology Issue: Volume 18:Issue 12(2017:Dec.) Page Start: 1590 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. (April 2017) Authors: Facchinetti, Francesco; Rossi, Giulio; Bria, Emilio; Soria, Jean-Charles; Besse, Benjamin; Minari, Roberta; Friboulet, Luc; Tiseo, Marcello Journal: Cancer treatment reviews Issue: Volume 55(2017) Page Start: 83 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗